DIGITAL THERAPEUTICS FOR ANXIETY AND DEPRESSION: A STRUCTURED REVIEW OF CLINICAL EVIDENCE, REGULATORY FRAMEWORKS, AND ACCESS DISPARITIES

Abstract

Background: The integration of Digital Therapeutics (DTx) into psychiatric care represents a paradigm shift in the management of anxiety and depression. With the continuous technological advancement of Software as a Medical Device (SaMD), its potential to alleviate shortages in psychiatric care is facing rigorous evaluation. As a result, ongoing studies aim to verify whether these technologies deliver genuine medical improvements, while simultaneously exploring the structural hurdles of deploying them within traditional clinical settings. Objective: This structured review evaluates the intersection of clinical evidence for DTx in treating Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD) with existing regulatory frameworks and socioeconomic barriers to equitable access. Methodology: An investigative sweep of the PubMed/MEDLINE and Google Scholar databases was executed to identify literature published from 2018 to 2026. Inclusion criteria focused on peer-reviewed RCTs and policy analyses of evidence-based DTx platforms. The assembled data underwent systematic organization via a thematic approach, with material being classified into three distinct categories: clinical efficacy, regulatory limitations, and accessibility equity. Results: Findings indicate that while AI-driven CBT and chatbot-delivered interventions demonstrate significant symptom reduction with moderate-to-high effect sizes, their long-term efficacy is moderated by user engagement patterns. Regulatory analysis reveals a fragmentation between the US FDA and European DiGA pathways, complicating global reimbursement. Furthermore, structural disparities—driven by the "digital divide" and low technological literacy—persistently limit the reach of these interventions among underserved populations. Conclusion: Digital interventions present an easily expandable mechanism for combating global psychiatric shortages; however, inconsistent legal guidelines and socioeconomic barriers heavily restrict their medical utility. Subsequent academic efforts need to emphasize multidimensional adoption models to prevent these technological advancements from worsening present-day medical inequalities.